GB2622130A - Composition - Google Patents
Composition Download PDFInfo
- Publication number
- GB2622130A GB2622130A GB2309785.0A GB202309785A GB2622130A GB 2622130 A GB2622130 A GB 2622130A GB 202309785 A GB202309785 A GB 202309785A GB 2622130 A GB2622130 A GB 2622130A
- Authority
- GB
- United Kingdom
- Prior art keywords
- extract
- rhus
- composition
- typhina
- glabra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 141
- 239000000284 extract Substances 0.000 claims abstract description 208
- 240000008599 Rhus glabra Species 0.000 claims abstract description 80
- 244000264648 Rhus coriaria Species 0.000 claims abstract description 78
- 235000013234 Rhus glabra Nutrition 0.000 claims abstract description 78
- 235000013178 Rhus coriaria Nutrition 0.000 claims abstract description 75
- 240000004901 Rhus typhina Species 0.000 claims abstract description 74
- 235000013831 Rhus typhina Nutrition 0.000 claims abstract description 72
- 244000294611 Punica granatum Species 0.000 claims abstract description 63
- 244000272264 Saussurea lappa Species 0.000 claims abstract description 63
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 60
- 235000006784 Saussurea lappa Nutrition 0.000 claims abstract description 60
- 239000003814 drug Substances 0.000 claims abstract description 33
- 239000007937 lozenge Substances 0.000 claims abstract description 28
- 238000000034 method Methods 0.000 claims abstract description 25
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 8
- 241000315672 SARS coronavirus Species 0.000 claims abstract description 7
- 208000001528 Coronaviridae Infections Diseases 0.000 claims abstract description 4
- 238000004806 packaging method and process Methods 0.000 claims abstract description 3
- 239000006286 aqueous extract Substances 0.000 claims description 19
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 238000000605 extraction Methods 0.000 description 33
- 235000013399 edible fruits Nutrition 0.000 description 30
- 150000001983 dialkylethers Chemical class 0.000 description 28
- 239000012675 alcoholic extract Substances 0.000 description 27
- 208000024891 symptom Diseases 0.000 description 26
- 239000012259 ether extract Substances 0.000 description 25
- 239000002904 solvent Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 235000015218 chewing gum Nutrition 0.000 description 19
- 229940112822 chewing gum Drugs 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 16
- 208000025721 COVID-19 Diseases 0.000 description 16
- 208000015181 infectious disease Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 239000000469 ethanolic extract Substances 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000036142 Viral infection Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 230000009385 viral infection Effects 0.000 description 8
- 206010013975 Dyspnoeas Diseases 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 230000000845 anti-microbial effect Effects 0.000 description 7
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 208000035143 Bacterial infection Diseases 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 206010017533 Fungal infection Diseases 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- 239000004599 antimicrobial Substances 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229940034610 toothpaste Drugs 0.000 description 6
- 239000000606 toothpaste Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 241000208225 Rhus Species 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 230000002538 fungal effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 239000002324 mouth wash Substances 0.000 description 5
- 229940051866 mouthwash Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 such as a colouring Substances 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010028735 Nasal congestion Diseases 0.000 description 4
- 206010068319 Oropharyngeal pain Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 235000014220 Rhus chinensis Nutrition 0.000 description 4
- 238000002591 computed tomography Methods 0.000 description 4
- 239000000287 crude extract Substances 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 208000016255 tiredness Diseases 0.000 description 4
- 230000003867 tiredness Effects 0.000 description 4
- 241000208223 Anacardiaceae Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 239000008122 artificial sweetener Substances 0.000 description 3
- 235000021311 artificial sweeteners Nutrition 0.000 description 3
- 235000012411 boiled sweets Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 208000010470 Ageusia Diseases 0.000 description 2
- 206010002653 Anosmia Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010008469 Chest discomfort Diseases 0.000 description 2
- 229920001412 Chicle Polymers 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004150 EU approved colour Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 240000001794 Manilkara zapota Species 0.000 description 2
- 235000011339 Manilkara zapota Nutrition 0.000 description 2
- 206010028817 Nausea and vomiting symptoms Diseases 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000012741 allura red AC Nutrition 0.000 description 2
- 239000004191 allura red AC Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 208000017574 dry cough Diseases 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 235000012732 erythrosine Nutrition 0.000 description 2
- 239000004174 erythrosine Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000012254 powdered material Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical class O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical class [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 239000004377 Alitame Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000226021 Anacardium occidentale Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004214 Fast Green FCF Substances 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Chemical class 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000039951 Lithocarpus glaber Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 229920000175 Pistacia lentiscus Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001938 Vegetable gum Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 238000011976 chest X-ray Methods 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Chemical class 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Chemical class C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Chemical class CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical class O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000000974 natural food coloring agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012169 petroleum derived wax Substances 0.000 description 1
- 235000019381 petroleum wax Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical class C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A composition comprising an extract of Aucklandia lappa Decne, an extract of Punica granatum and an extract of at least one of Rhus coriaria L., Rhus glabra and Rhus typhina. A method of preparing a lozenge comprising admixing a therapeutically effective amount of the extract composition with a lozenge base and forming a lozenge, and a kit for providing a medicament comprising packaging comprising the extract composition and instructions for administering the medicament are also included. The extracts of A. lappa and P. granatum may be in a ratio between 4:1 and 1:1. The A. lappa extract is preferably an aqueous root extract and the P. granatum extract is preferably an aqueous peel extract. The composition may comprise an extract of each of R. coriaria L., R. glabra and R. typhina, which may be in a 1:1:1 ratio. The composition may consist essentially of an extract of each of A. lappa, P. granatum, R. coriaria L., R. glabra and R. typhina. The composition may be for oral administration and may be for use as a medicament, preferably for use in treatment of respiratory tract infections and particularly for use in treatment of coronavirus infections, such as SARS-CoV and SARS-CoV-2 (COVID-19).
Description
Composition
FIELD
The present invention relates to a composition comprising plant extracts, which composition may be useful as a medicament.
BACKGROUND
Infections, including bacterial, viral and fungal infections, are relatively common illnesses and represent serious health challenges Examples of infections that are particularly challenging include respiratory infections, such as infections of the upper respiratory tract, especially chronic rhinosinusitis (CRS).
Recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has emerged as a novel coronavirus, which is a highly transmittable and pathogenic viral infection. SARS-CoV2 causes coronavirus disease (COVID-19 disease), which is a highly infectious respiratory illness. COVID-19 disease was declared a pandemic by the World Health Organization and can lead to respiratory failure.
There is a desire to provide effective therapies for treating infections, including respiratory infections, such as CRS and COVID-19 disease, that offer patients improved outcomes, including the potential for reducing morbidity and mortality.
Plant-derived medicaments remain an important resource, especially in developing countries, to combat serious diseases. There has been increasing interest in natural products from different sources particularly from higher plants for the discovery of new antimicrobial and antioxidant agents, such as tannins, terpenoids, alkaloids, and flavonoids, which have been demonstrated to have in vitro antimicrobial properties.
It is an aim of the present invention to provide a plant-derived medicament that may be used to treat infections such as respiratory infections and improve on the prior art.
SUMMARY
The present invention provides a composition asset forth in the appended claims. Other features of the invention will be apparent from the dependent claims, and the description, which follows.
According to the present invention, there is provided a composition comprising: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (Di) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina.
As used herein, the term "extract" means a substance (for example a pharmaceutically active substance) obtained by extracting (or removing) that substance from a raw material. The extracts described herein may therefore be referred to as an extracted substance. Extracts may comprise a single (extracted) substance or multiple (extracted) substances. Typically, an extract comprises multiple (extracted) substances. References herein to extracts refer to both the substance obtained directly from the extraction process and to extracts that are further purified following extraction from a raw material.
The extracts as discussed herein may be provided in any suitable form, such as a liquid, paste or powder (such as a dried powder, for example a freeze-dried powder).
The extracts as discussed herein may be obtained by any suitable extraction method. Suitable extraction methods would be known to persons skilled in the art and include solvent extraction.
The extracts as discussed herein may be obtained by a solvent extraction method. Any suitable extraction solvent may be used in a solvent extraction method. For example, the extraction solvent may comprise water, in which case the extract may be referred to as an aqueous extract.
Suitable extraction solvents may be selected from water, an alcohol, and an ether, and mixtures thereof. For example, suitable extraction solvents may be selected from water, a Cl to 04 or a C2 to C4 alcohol, and a dialkyl ether (such as a C2 to C5 or C2 to C4 dialkyl ether), and mixtures thereof.
Suitable extraction solvents may comprise water. In this case, the extract may be referred to as an aqueous extract.
Suitable extraction solvents may comprise an alcohol, such as a Cl to C4 or a 02 to 04 alcohol, for example methanol or ethanol (suitably ethanol). In this case, the extract may be referred to as an alcoholic extract, for example an ethanolic extract.
Suitable extraction solvents may comprise water and an alcohol, such as a Cl to 04 or a 02 to 04 alcohol. For example, a suitable extraction solvent may comprise water and methanol. For example, a suitable extraction solvent may comprise water and ethanol. In this case, the extract may be referred to as an aqueous alcoholic extract, for example an aqueous ethanolic extract.
Suitable extraction solvents may comprise water and an alcohol in any suitable proportions, as would be determined by a person skilled in the art. For example, a suitable extraction solvent may comprise from 2 to 8 wt% water and from 92 to 98 wt% alcohol (such as a Cl to C4 or a C2 to C4 alcohol, for example methanol or ethanol, suitably ethanol).
Suitably the extract is an aqueous extract, for example an aqueous alcoholic extract, such as an aqueous ethanolic extract.
Suitable extraction solvents may comprise an ether, such as a dialkyl ether, for example a C2 to C5 or C2 to C4 dialkyl ether. For example, a suitable extraction solvent may have the formula R10R2 wherein each of R1 and R2 is independently a C2 to C5 or C2 to C4 alkyl group. For example, a suitable extraction solvent may comprise diethyl ether, dibutyl ether and/or combinations thereof In this case, the extract may be referred to as an ether extract.
An extract such as an aqueous extract may be used directly in the form in which it is prepared, or may be modified to provide another suitable form of the extract, For example, the extract may be a dehydrated extract, in which case the extract (for example aqueous extract) is subjected to dehydration. For example, the dehydrated extract may be a lyophilised (or "freeze-dried") extract. The extract may be a reconstituted dehydrated extract, in which case the dehydrated extract is reconstituted in water.
The composition comprises (i) an extract of Aucklandia lappa Decne.
Aucklandia lappa Decne, otherwise known as Saussurea lappa (Decne), is a traditional herb containing approximately 1 to 2.5 wt% of refined oils. Aucklandia lappa Decne is commonly referred to as AID.
Suitably the extract of Aucklandia lappa Decne is an extract of the root of Aucklandia lappa Decne.
Suitably the extract of Aucklandia lappa Decne is an aqueous extract of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is an alcoholic extract of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is an aqueous alcoholic extract of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is an aqueous ethanol ic extract of Aucklandia lappa Decne.
Suitably the extract of Aucklandia lappa Decne is an aqueous extract of the root of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is an alcoholic extract of the root of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is an aqueous alcoholic extract of the root of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is an aqueous ethanolic extract of the root of Aucklandia lappa Decne.
Suitably the extract of Aucklandia lappa Decne is an ether extract of Aucklandia lappa Decne.
Suitably the extract of Aucklandia lappa Decne is a dialkyl ether (for example a 02 to 05 or C2 to 04 dialkyl ether) extract of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is a diethyl ether or dibutyl ether extract of Aucklandia lappa Decne.
Suitably the extract of Aucklandia lappa Decne is an ether extract of the root of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of the root of Aucklandia lappa Decne. Suitably the extract of Aucklandia lappa Decne is a diethyl ether or dibutyl ether extract of the root of Aucklandia lappa Decne.
The extract of Aucklandia lappa Decne may be provided in powdered form, such as in lyophilized powder form.
The composition comprises (ii) an extract of Punica granatum.
Punica granatum is a widely cultivated deciduous shrub grown for its fruits and known simply as "pomegranate".
Suitably the extract of Punica granatum is an extract of the peel of Punica granatum.
Suitably the extract of Punica granatum is an aqueous extract of Punica granatum. Suitably the extract of Punica granatum is an alcoholic extract of Punica granatum. Suitably the extract of Punica granatum is an aqueous alcoholic extract of Punica granatum. Suitably the extract of Punica granatum is an aqueous ethanolic extract of Punica granatum.
Suitably the extract of Punica granatum is an aqueous extract of the peel of Punica granatum.
Suitably the extract of Punica granatum is an alcoholic extract of the peel of Punica granatum. Suitably the extract of Punica granatum is an aqueous alcoholic extract of the peel of Punica granatum. Suitably the extract of Punica granatum is an aqueous ethanolic extract of the peel of Punica granatum.
Suitably the extract of Punica granatum is an ether extract of Punica granatum. Suitably the extract of Punica granatum is a dialkyl ether (for example a 02 to C5 or 02 to 04 dialkyl ether) extract of Punica granatum. Suitably the extract of Punica granatum is a diethyl ether or dibutyl ether extract of Punica granatum.
Suitably the extract of Punica granatum is an ether extract of the peel of Punica granatum. Suitably the extract of Punica granatum is a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of the peel of Punica granatum. Suitably the extract of Punica granatum is a diethyl ether or dibutyl ether extract of the peel of Punica granatum.
The extract of Aucklandia lappa Decne and the extract of Punica granatum may be suitably provided in the composition in a weight ratio of from 5:1 to 1:1, such as from 4:1 to 1:1, for example in a weight ratio of 4:1.
The extract of Punica granatum may be provided in powdered form, such as in lyophilized powdered form.
The extract of Aucklandia lappa Decne and the extract of Punica granatum may both be provided in lyophilized powder form.
The composition comprises (iii) one or more extracts of Rhus coriaria L., Rhus glabra and Rhus typhina.
Rhus coriaria L., commonly called Sicilian sumac, tanner's sumach, or elm-leaved sumach, is a deciduous shrub to small tree in the cashew family Anacardiaceae. It is native to southern Europe and western Asia.
Rhus glabra, also known as the smooth sumac, white sumac, upland sumac, or scarlet sumac, is a species of sumac in the family Anacardiaceae. It is native to North America.
Rhus typhina, commonly known as the staghorn sumac, is a species of flowering plant in the family Anacardiaceae. It is native to eastern North America.
Suitably the extracts of Rhus coriaria L., Rhus glabra and Rhus typhina are extracts of the fruit of Rhus coriaria L., Rhus glabra and Rhus typhina.
The one or more extracts of Rhus coriaria L., Rhus glabra and Rhus typhina may be provided in powdered form.
The composition may comprise extracts of Rhus coriaria L. and Rhus glabra, and optionally an extract of Rhus typhina.
The composition may comprise extracts of Rhus coriaria L. and Rhus typhina, and optionally an extract of Rhus glabra.
The composition may comprise extracts of Rhus glabra and Rhus typhina, and optionally an extract of Rhus coriaria L. The composition may comprise extracts of Rhus coriaria L, Rhus glabra and Rhus typhina.
Suitably the extract of Rhus coriaria L. is an aqueous extract of Rhus coriaria L. Suitably the extract of Rhus coriaria L is an alcoholic extract of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is an aqueous alcoholic extract of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is an aqueous ethanolic extract of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is an ether extract of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is a diethyl ether or dibutyl ether extract of Rhus coriaria L. Suitably the extract of Rhus glabra is an aqueous extract of Rhus glabra. Suitably the extract of Rhus glabra is an alcoholic extract of Rhus glabra. Suitably the extract of Rhus glabra is an aqueous alcoholic extract of Rhus glabra. Suitably the extract of Rhus glabra is an aqueous ethanolic extract of Rhus glabra.
Suitably the extract of Rhus glabra is an ether extract of Rhus glabra. Suitably the extract of Rhus glabra is a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of Rhus glabra. Suitably the extract of Rhus glabra is a diethyl ether or dibutyl ether extract of Rhus glabra.
Suitably the extract of Rhus typhina is an aqueous extract of Rhus typhina. Suitably the extract of Rhus typhina is an alcoholic extract of Rhus typhina. Suitably the extract of Rhus typhina is an aqueous alcoholic extract of Rhus typhina. Suitably the extract of Rhus typhina is an aqueous ethanolic extract of Rhus typhina.
Suitably the extract of Rhus typhina is an ether extract of Rhus typhina. Suitably the extract of Rhus typhina is a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of Rhus typhina. Suitably the extract of Rhus typhina is a diethyl ether or dibutyl ether extract of Rhus typhina.
Suitably the extract of Rhus coriaria L. is an aqueous extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is an alcoholic extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus coriaria L is an aqueous alcoholic extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is an aqueous ethanolic extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is an ether extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is a dialkyl ether (for example a 02 to 05 or C2 to 04 dialkyl ether) extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus coriaria L. is a diethyl ether or dibutyl ether extract of the fruit of Rhus coriaria L. Suitably the extract of Rhus glabra is an aqueous extract of the fruit of Rhus glabra. Suitably the extract of Rhus glabra is an alcoholic extract of the fruit of Rhus glabra. Suitably the extract of Rhus glabra is an aqueous alcoholic extract of the fruit of Rhus glabra. Suitably the extract of Rhus glabra is an aqueous ethanolic extract of the fruit of Rhus glabra.
Suitably the extract of Rhus glabra is an ether extract of the fruit of Rhus glabra. Suitably the extract of Rhus glabra is a dialkyl ether (for example a 02 to 05 or 02 to 04 dialkyl ether) extract of the fruit of Rhus glabra. Suitably the extract of Rhus glabra is a diethyl ether or dibutyl ether extract of the fruit of Rhus glabra.
Suitably the extract of Rhus typhina is an aqueous extract of the fruit of Rhus typhina. Suitably the extract of Rhus typhina is an alcoholic extract of the fruit of Rhus typhina. Suitably the extract of Rhus typhina is an aqueous alcoholic extract of the fruit of Rhus typhina. Suitably the extract of Rhus typhina is an aqueous ethanolic extract of the fruit of Rhus typhina.
Suitably the extract of Rhus typhina is an ether extract of the fruit of Rhus typhina. Suitably the extract of Rhus typhina is a dialkyl ether (for example a 02 to C5 or C2 to 04 dialkyl ether) extract of the fruit of Rhus typhina. Suitably the extract of Rhus typhina is a diethyl ether or dibutyl ether extract of the fruit of Rhus typhina.
The composition may comprise an aqueous extract of Rhus coriaria L, Rhus glabra and Rhus typhina.
The composition may comprise an alcoholic extract of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise an aqueous alcoholic extract of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise an aqueous ethanolic extract of Rhus coriaria L., Rhus glabra and Rhus typhina.
B
The composition may comprise an aqueous extract of the fruit of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise an alcoholic extract of the fruit of Rhus coriaria L., Rhus glabra 5 and Rhus typhina.
The composition may comprise an aqueous alcoholic extract of the fruit of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise an aqueous ethanolic extract of the fruit of Rhus coriaria L, Rhus glabra and Rhus typhina.
The composition may comprise an ether extract of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise a diethyl ether or dibutyl ether extract of Rhus coriaria L., Rhus 20 glabra and Rhus typhina.
The composition may comprise an ether extract of the fruit of Rhus coriaria L. Rhus glabra and Rhus typhina.
The composition may comprise a dialkyl ether (for example a C2 to C5 or C2 to C4 dialkyl ether) extract of the fruit of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise a diethyl ether or dibutyl ether extract of the fruit of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition may comprise (as component (iii)) an extract of Rhus coriaria L, Rhus glabra and Rhus typhina in a 1:1:1 weight ratio.
The composition may comprise (i) an extract of Aucklandia lappa Decne, OD an extract of Punica granatum and (Hi) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina in a weight ratio (i.e. of (i):(ii);(iii)) of from 5:1:4 to 1:1:1, such as from 4:1:3 to 1:1:1, for example in a weight ratio of 4:1:3.
The composition may comprise the extracts (i), (ii) and (Hi) in an amount of 40 to 60 wt % of extract (i), 10 to 15 wt % of extract (H) and 30 to 45 wt % of extract (iii).
The present invention may provide a composition that consists essentially of: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina.
The present invention may provide a composition that consists of: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina.
The present invention may provide a composition that consists essentially of: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of Rhus coriaria L, Rhus glabra and Rhus typhina.
The present invention may provide a composition that consists of: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of Rhus coriaria L., Rhus glabra and Rhus typhina.
The composition of the invention may be in a form suitable for oral, topical or parental administration or for administration by inhalation.
The composition of the invention may be in a form suitable for oral or topical administration. The composition of the invention may be in a form suitable for inhalation or parenteral administration. Oral administration may involve swallowing, so that the composition enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the composition enters the blood steam directly from the mouth. Administration by inhalation may be as a finely divided powder or a liquid aerosol (for example for delivery by means of an inhaler or nebulizer device). Parenteral administration may be as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular dosing or a suppository for rectal dosing. Compositions suitable for topical administration may be applied to any suitable skin surface.
Compositions suitable for oral administration include solid and liquid compositions. Suitable solid compositions include tablets, capsules (for example containing particulates, liquids, or powders), lozenges (including liquid-filled), chews (including chewing gums); multi-and nano-particulates, gels pastes, solid solution, liposome, films and sprays. Suitable liquid compositions include suspensions, solutions, syrups and elixirs. Such compositions may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid compositions may also be prepared by the reconstitution of a solid composition, for example, from a sachet.
The composition of the invention may be orally administered once per day.
The composition of the invention may be orally administered more than once per day, such as 2 to 10 times, for example 4 to 8 times a day.
Suitably, the composition of the invention may be formulated as a chew (such as a chewing gum), as particulates (such as to form a filling for a sachet), a mouthwash, a toothpaste, a pastille, a lozenge, a boiled sweet, a jelly or a powder.
The composition of the invention may be formulated as a chewing gum. This may alternatively be referred to as a chicle. The chewing gum may be an acidulated chewing gum. The chewing gum may be a non-acidulated chewing gum.
The compositions of the invention may be obtained by conventional procedures using conventional methods in the art.
The compositions of the invention may comprise additional ingredients, such as a colouring, sweetening, flavouring, softening and/or preservative agent. The compositions of the invention may comprise a filler and/or carrier.
When the composition of the invention comprises additional ingredients, the composition may comprise from 20 to 80 wt % of the extracts (i), (ii) and (iii) and from 80 to 20 wt % of the additional ingredients.
Suitable colouring agents comprise natural food dyes or artificial colourings, such as Fast green (E143), Allura red (E129), brilliant blue (E133), Erythrosine (pink) (E127), tartrazine (E102), sunset yellow (El 10) and indigotine (El 32).
Suitable softening agents comprise waxes, such as natural and synthetic waxes, hydrogenated vegetable oils, petroleum waxes for example, paraffin waxes, microcrystalline waxes polyurethane waxes and polyethylene waxes.
The compositions of the invention for oral administration may comprise a flavouring agent such as a taste covering agent. Such taste covering agents may, for example, comprise menthol or peppermint oil.
The flavouring agent, when present, may be present in an amount of from 1 to 5 wt%, such as from Ito 3 wt%.
The compositions of the invention for oral administration may comprise a sweetening agent, such as a natural or artificial sweetener. Examples of suitable sweeteners may include aspartame and polyol sweeteners, such as (crystalline) xylitol, sorbitol, mannitol and erythritol.
Further examples of suitable sweeteners include sucrose, lactose, dextrose, maltose, dextrin, dried inverted sugar, fructose, levulose, galactose, corn syrup, hydrogenated starch hydrolysates, maltitol, sucralose, aspartame, salts of acesulfame potassium, alitame, saccharin and its salts, cyclamic acid and its salts, glycyrrhizin, dihydrochalcones, thaumatin and monellin.
The sweetening agent, when present, may be present in an amount of from Ito 5 wt%, such as from 1 to 3 wt%.
When the composition of the invention is formulated as a chewing gum, the chewing gum suitably comprises a composition according to the invention and a chewing gum base. The chewing gum base may comprise natural latex, vegetable gum, arabian gum and/or mastic gum. The chewing gum base may be present in an amount of from 8 to 25 wt% of the chewing gum. The chewing gum may further comprise a sugar, artificial sweetener, and/or wax coating.
The composition of the invention may be formulated as a sachet filling. By a sachet we mean a container (such as an envelope or bag) which contains the sachet filing. The sachet filing may be in the form of a granulate, particulates or spheronised particles. Suitably, the sachet filling may be added to liquid, for example, water, for oral ingestion. When formulated as a sachet filing, the composition suitably has long storage stability.
The composition of the invention may be formulated as a mouthwash. A mouthwash is an oral hygiene product. Suitably the mouthwash is a liquid composition. A mouthwash may comprise a carrier, for example an alcohol compound.
The composition of the invention may be formulated as a toothpaste. Toothpaste is an oral hygiene product. Suitably the toothpaste is formulated as a paste or gel. The toothpaste may comprise an abrasive, fluoride, a flavouring agent and a detergent. The toothpaste may further comprise a surfactant.
The composition of the invention may be formulated as a lozenge. Lozenges are solid preparations that contain one or more active ingredients, usually in a flavoured, sweetened base, that are intended to dissolve or disintegrate slowly in the mouth. Lozenges can be prepared by molding (gelatin and/or fused sucrose and sorbitol base) or by compression of sugar-based tablets. Moulded lozenges are sometimes alternatively referred to as pastilles, whereas compressed lozenges may be alternatively referred to as troches.
The composition of the invention may be formulated as a boiled sweet or hard candy. Typically, boiled sweets are a sugar candy prepared from one or more sugar-based syrups that are heated to a temperature of 160°C.
The composition of the invention may be formulated as a jelly or jello, which typically comprise gelatin. The jelly may comprise further additives such as gelling agents, colouring agents, artificial sweeteners, emulsifiers and antioxidants.
The composition of the invention may be formulated as a powder. Suitably the powder may be added to foods or liquids (such as drinks) for ingestion.
The composition of the invention may be an anti-microbial composition. The anti-microbial composition may be useful for disinfecting surfaces, including the skin. Thus, the present invention may provide an anti-microbial composition comprising a composition as described herein. The anti-microbial composition may comprise a personal hygiene composition, such as a cleansing composition (for example a soap or shampoo composition).
The composition of the invention may be a nutritional supplement composition. The nutritional supplement composition may be useful for strengthening the immune system against bacterial, fungal and/or viral infections. Thus, the present invention may provide a nutritional supplement composition comprising a composition as described herein.
According to the present invention, there is provided the composition as described herein for use as a medicament.
According to the present invention, there is provided the composition as described herein for use as an anti-microbial.
According to the present invention, there is provided the composition as described herein for use as an immune boost agent, i.e. to strengthen the immune system against bacterial, fungal and/or viral infections.
According to the present invention, there is provided the composition as described herein for use in the treatment of an infection, such as a bacterial, fungal or viral infection. According to the present invention, there is provided the composition as described herein for use in the treatment of a viral infection. For example, the infection referred to herein may be an infection of the throat, skin, oral cavity, nasal cavity and/or ear cavity.
According to the present invention, there is provided the composition as described herein for use in the treatment of a respiratory tract infection, for example an upper and/or lower respiratory tract infection.
According to the present invention, there is provided the composition as described herein for use in the treatment of an infection of the upper respiratory tract, such as chronic rhinosinusitis (CRS).
According to the present invention, there is provided the composition as described herein for use in the treatment of a coronavirus infection, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and/or severe acute respiratory syndrome coronavirus 2 (SARS-00V2).
According to the present invention, there is provided a method for strengthening the immune system against bacterial, fungal and/or viral infections in a warm-blooded animal, which comprises administering to said warm-blooded animal a composition as described herein.
According to the present invention, there is provided a method for treating an infection, such as a bacterial, fungal or viral infection, in a warm-blooded animal, which comprises administering to said warm-blooded animal a composition as described herein.
According to the present invention, there is provided a method for treating a viral infection in a warm-blooded animal, which comprises administering to said warm-blooded animal a composition as described herein.
According to the present invention, there is provided a method for treating a respiratory viral infection in a warm-blooded animal, which comprises administering to said warm-blooded animal a composition as described herein.
According to the present invention, there is provided a method for treating an infection of the upper respiratory tract, such as chronic rhinosinusitis (CRS), in a warm-blooded animal, which comprises administering to said warm-blooded animal a composition as described herein.
According to the present invention, there is provided a method for treating a coronavirus infection, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and/or severe acute respiratory syndrome coronavirus 2 (SARS-00V-2) infection, in a warm-blooded animal, which comprises administering to said warm-blooded animal a composition as described herein.
The amount of the extracts as described herein (i.e. the active ingredient) and the specific ratios thereof that is included in a single dosage of the composition will necessarily vary depending on the patient being treated and the particular route of administration.
A therapeutically effective amount of the components (i), (ii) and (iii) of the composition of the invention, for example to treat an infection, may be as follows wherein the effective amounts may be administered as one or more doses: (i) Extract of Aucklandia lappa Decne: 250 mg to 2. Og, preferably 125 mg to 1 g (ii) Extract of Punica granatum: 250 mg to 1 g, preferably 31.25 mg to 250 mg (iii) Extract of one or more of Rhus coriaria L., Rhus glabra, and Rhus typhina: 250 mg to 1 g, preferably 31.25mg to 250 mg The composition for use as described herein may treat and/or relieve symptoms including fever, thrombosis, impaired immune system, chills, cough, nasal congestion, sore throat, tiredness, nausea/vomiting, fatigue, muscle/body pain, diarrhoea, headache, loss of appetite, loss of taste, loss of smell, loss of concentration, dyspnoea, breath shortness, and/or sleep difficulty.
The composition of the invention may be administered as a sole therapy, or may be administered in combination with an additional therapeutic agent. Additional therapeutic agent(s) may be administered simultaneously, separately or sequentially with the composition of the invention.
According to the present invention, there is provided a method of preparing a lozenge comprising: admixing a therapeutically effective amount of a composition of the invention with a lozenge base to provide a lozenge composition; and forming the lozenge composition into a lozenge.
According to the present invention, there is provided a method of preparing a chewing gum 35 comprising: admixing a therapeutically effective amount of a composition of the invention with a chewing gum base to provide a chewing gum composition; and forming the chewing gum composition into a chewing gum.
The lozenge may be formed by any suitable method, such as by moulding or compressing.
According to the present invention, there is provided a kit for providing a medicament for oral administration, the kit comprising packaging containing (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina; and instructions for administration of the medicament.
The term "comprising" or "comprises" means including the component(s) specified but not to the exclusion of the presence of other components. The term "consisting essentially of or "consists essentially of means including the components specified but excluding other components except for materials present as impurities, unavoidable materials present as a result of processes used to provide the components, and components added for a purpose other than achieving the technical effect of the invention. The term "consisting of or "consists of means including the components specified but excluding other components.
Whenever appropriate, depending upon the context, the use of the term "comprises" or "comprising" may also be taken to include the meaning "consists essentially of' or "consisting essentially of', and may also be taken to include the meaning "consists of' or "consisting of.
The optional features set out herein may be used either individually or in combination with each other where appropriate and particularly in the combinations as set out in the accompanying claims. The optional features for each aspect or exemplary embodiment of the invention, as set out herein are also applicable to all other aspects or exemplary embodiments of the invention, where appropriate. In other words, the skilled person reading this specification should consider the optional features for each aspect or exemplary embodiment of the invention as interchangeable and combinable between different aspects and exemplary embodiments.
References to "treating" or "treatment" include prophylaxis as well as the alleviation of established symptoms of a disease or medical condition. "Treating" or "treatment" of a disease or medical condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the disease or medical condition developing in a human that may be afflicted with or predisposed to the disease or medical condition but does not yet experience or display clinical or subclinical symptoms thereof, (2) inhibiting the disease or medical condition, Le. arresting, reducing or delaying the development of the disease or medical condition, or a relapse thereof an case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, Le. causing regression of the disease or medical condition or at least one of its clinical or subclinical symptoms.
A "therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, the mode of administration and the age, weight, etc. of the mammal to be treated.
EXAMPLES
The invention will now be illustrated by the following non-limiting examples.
Example 1 Preparation of the Extracts 120g of each of the root of Aucklandia lappa Decne (herein "AID"), the peel of Punica granatum (herein pomegranate or "PgP"), the beads of Rhus coriaria L. Therein "Ron, Rhus Glabra Therein "RG"), and Rhus typhina (herein "Rt") were weighed and washed thoroughly in de- ionized water, "saline water" (i.e. 100g of granule salt in 1 L of deionized water) and again in de-ionized water to remove any dirt, soil and/or undesirable contaminants, and then allowed to dry in an oven at 45°C overnight. The dried materials were then weighed and ground into a powdered state using a "Professional Spice Grinder" model no. WSG30K.
The following extraction procedures were carried out for each individual ground (powdered) plant material: Ethanolic extraction Each powdered material was mixed with an extraction solvent comprising 95% v/v of (F.C.C.) Food Grade Ethanol and 5% v/v water to form a suspension. The suspension was incubated at room temperature for 72 hours under continuous vigorous shaking. The suspension was then filtered, and the filtrate was dried at a temperature of about 60°C (using a rotary evaporator) until it became viscous to provide a crude extract. The crude extract was resuspended in an extraction solvent comprising 95% v/v of (FCC) Food Grade Ethanol and 5% v/v water and incubated overnight at a temperature of 75°C to 85°C on a conventional magnetic heat block with the magnetic stirrer. The suspension was then cooled on ice for 15 minutes, which allowed a solid crystal-like material to be formed in the suspension solution. The solid was then removed by filtration, and the filtrate was further dried at 60°C (using a rotary evaporator) and then lyophilized using freeze-drying. The lyophilized powder obtained from each plant was then re-weighed and recorded accordingly as shown below: 120g of the Aucklandia lappa Decne (AID) raw material gave 5.8g of the filtrate extracted material 120g of the Punica granatum (PgP) raw material gave 3.1g of the filtrate extracted material 120g of Rhus coriaria L. (RcL) raw material gave 4.0g of the filtrate extracted material 120g of Rhus glabra (RG) raw material gave 3.9g of the filtrate extracted material 120g of "Rhus typhina (Rt) raw material gave 3.7.g of the filtrate extracted material Further extraction solvents The same extraction process as for the ethanolic extraction above was carried out using deionised water as the extraction solvent in the place of the ethanolic solvent.
The same process was also carried out as for the ethanolic extraction above using diethyl ether or dibutyl ether as the extraction solvent in the place of the ethanolic solvent, except that several process parameters were changed. The process using diethyl ether or dibutyl ether was as follows: Each powdered material was mixed with the extraction solvent to form a suspension. The suspension was incubated at 4°C for 72 hours under continuous vigorous shaking. The suspension was then filtered, and the filtrate was dried at a temperature of about 30°C (using a rotary evaporator) until it became viscous to provide a crude extract. The crude extract was resuspended in the extraction solvent incubated overnight at room temperature with the magnetic stirrer. The suspension was then cooled on ice for 15 minutes, which allowed a solid crystal-like material to be formed in the suspension solution. The solid was then removed by filtration, and the filtrate was further dried at 30°C (using a rotary evaporator) and then lyophilized using freeze-drying. The lyophilized powder obtained from each plant was then re-weighed and recorded accordingly The range of amounts of extracted material in lyophilized powder form obtained from each plant using the extraction solvents deionised water, diethyl ether or dibutyl ether is shown below: 1kg of Aucklandia lappa Decne (AID) raw material gave 111-120g of the filtrate extracted material lkg of Punica granatum (PgP) raw material gave 98-117g of the filtrate extracted material 1kg of Rhus coriaria L. (RcL) raw material gave 123-140g of the filtrate extracted material 1kg of Rhus glabra (RG) raw material gave 145-165g of the filtrate extracted material 1kg of "Rhus typhina (Rt) raw material gave 87-115g of the filtrate extracted material Example 2 Preparation of a medicament in a lozenge formulation Each "lozenge" (or chicle) comprises a total of 250 mg of the substances as illustrated in Table 1 below (wherein the extracts were prepared according to Example 1 using the ethanolic extraction method).
Table 1
Component Common Name Weight Aucklandia lappa Decne root extract Aucklandia or Costus 125mg Punica granatum peel extract Pomegranate peel 31.25mg Rhus coriaria L. extract Sicilian sumac 31.25mg Rhus glabra extract Smooth sumac 31.25mg Rhus typhina extract Staghom sumac 31.25mg Stevia Sweetener 625mg Glycol El 520 Flavour 12.5mg The lyophilized powder obtained for each plant extract from Examp e 1 was used and weighed according to Table 1 (in a weight ratio of 4:1:1:1:1 in the order listed in Table 1).
12.5g of Stevia was mixed with 500m1 of water in a glass beaker with a magnetic stirrer on a heat block at 80°C. Once the solution became viscous, a mixture 2.5g AID and 0.625g of each of PgP, RcL, RG and Rt were added, followed by adding 0.25g Glycol E1520. The temperature was adjusted to 60°C with continuous stirring. When the mixture was well mixed the resulting composition was poured into a "lozenge silicone mould" (comprising a plurality of lozenge compartments) and allowed to cool to room temperature for 2 to 3 hours until the mixture solidified. For sterilization and health and safety purposes, the procedure was carried out under a Class II cell culture fume hood.
An effective dosage of the lozenges against COVID-19 was found to be 4 to 8 lozenges per day for 2 to 3 days depending on the infection status of the subject and the clinician's advice.
EXAMPLE 3 Preparation of a medicament in a Sachet (or infused-bag) Formulation A sachet was filled with the following extracts (mixed as powders) obtained as described in Example 1 (using the ethanolic extraction method), as shown in the Table 2 below.
Table 2
Components and Scientific name Common Name Weight Aucklandia lappa Decne root extract Aucklandia or Costus 1g Punica granatum peel extract Pomegranate peel 250mg Rhus coriaria L. extract Sicilian sumac 250mg Rhus glabra extract Smooth sumac 250mg Rims &prune extract Staghorn sumac 250mg Stevia Sweetener 0.7g Glycol E1520 Flavour 125mg For use the sachet content was emptied into a cup of 100m1-150m1 boiled water and left for 10 minutes prior to oral intake.
The prepared composition in a sachet form can be given to a patient at a dosage of 2 to 3 sachets per day.
EXAMPLE 4 Clinical Trial A clinical trial was conducted as follows: Safety Aspects: Safety was strictly followed in all aspects of the clinical trial and in accordance with international safety rules and regulations. Clinicians and professional scientists followed strictly all safety aspects throughout the entire investigation including medicament preparation and its use as well as COVID-19 patient's safety aspects.
Clinical Trial: A total of 200 COVID-19 volunteers (male and female) patients were involved in the clinical trial.
The 200 subjects were equally divided into two groups A and B. Group A was treated with the medicament in lozenge formulation according to Example 2 whereas group B was treated with the medicament in sachet formulation according to Example 3. No groups were treated with a placebo due to ethical issues. All patients came into the clinics due to COVID-19 with initial symptoms such as itching in the throat, sore throat, nasal congestion, dry cough, high temperature, shortness of breath, loss of smell and taste. The patients were all adults (as stated below) with no other serious medical complications (except two patients who experienced wet gangrene and an ischemic stroke, respectively). All patients were confirmed to be infected with SARS-CoV-2 by PCR testing. The patients were monitored carefully by the senior consultants in charge before the clinical trial started as well as after treatment. Patients were carefully monitored under closed supervision and evaluated by a team of clinicians and nurses.
Evaluation of patients' health status was regularly and continuously assessed by the in charge consultant who monitored the administration of the therapy as required.
Patients' Criteria: All patients enrolled in this clinical trial were registered and monitored for a minimum of 7 days, unless otherwise stated (three days of which were under the new therapy).
Inclusion and Exclusion Criteria: Inclusion criteria: Any adult patient who is SARS-CoV-2 positive, from any nationality, was accepted Exclusion Criteria: Pregnant women and children (less than 16 years old) were excluded.
Patients were chosen according to the following criteria: The patients agreed voluntarily to use the medicament of Example 2 or 3 and in accordance with the international ethics practice.
Patient's Observation and Evaluation: Patients were carefully observed and evaluated according to the following measures: * Patients were required to take a PCR test and CT-Scan to indicate the presence of the SARS-CoV-2 initially and after the therapy ended.
* Complete diagnostic records were recorded/maintained, including physical signs and pulse conditions.
* Clinical monitoring and follow-up were performed by the in-charge medical consultants of both groups.
Criteria for Curative Effect: The various criteria were divided according to the scientific research plan and categorized as follows: Recovery: -If SARS-CoV-2 testing PCR and/or RT-PCR is negative.
-There are no symptoms, no physical signs, and no other complaints.
Evident Effect: If SARS-CoV-2 appears negative or undetectable and the symptoms and physical signs recover fundamentally back to normal.
With Effect: If SARS-CoV-2 testing PCR appears positive, but the symptoms and physical signs are relieved.
No Effect: If there are no dramatic changes in the SARS-CoV-2 status and the symptoms get worse, or The patient requires further medical care in the hospital.
Note: Each SARS-CoV-2 positive patient case was studied on its own and carefully followed and continuously assessed by the professional medical team.
The strategy of the regime therapy is summarized as follows: * A comprehensive analysis of the curative effect according to the clinical symptoms was studied, evaluated, and recorded.
* The SARS-CoV-2 infection was confirmed by the available testing assays.
* The profile of the patient, including the period of the disease was examined at the start of the clinical trial and after the completion of the trial.
Pre-Treatment Status -Physical Examination: All the COVID-19 patients were examined for common COVID-19 symptoms and symptoms of depression, weakness, and weight loss associated with loss of appetite, and developed fever.
Treatment with the Medicament:
SUBJECTS
Two hundred (200) human subjects were qualified to partake if they are otherwise healthy or COVID-19 free, have at least moderate manifestation severity, and report side effects and/or symptoms of 48 hours or less duration. Symptoms are COVID-19 symptoms; headache, fever, tiredness, and dry cough symptoms, in particular, fever, pain, weakness, dryness, and/or inflammation of the throat.
Ethics and Consent form Although the medicament is a food supplement in its nature full consent in parallel with ethical approval has been given to the clinicians by the patient prior to the start of the clinical trial.
STUDY MEDICATIONS
Both, group A and group B were given the medicament in their assigned formulation as stated earlier i.e., group A received the medicament in a lozenge form and group B received the medicament in a sachet form. Instruction for dosage was stated clearly in EXAMPLE 2 and EXAMPLE 3.
STUDY PROCEDURES
All participated patients involved in this clinical phase trial were between the age of 25 to 80 years. The patients were confirmed to have COVID-19 clinically by their association with the symptoms stated above as well as confirmed by the PCR and/or CT scan tests.
RESULTS
Results showed that all patients in both groups found that some of their symptoms stated above were relieved within a period of 4 to 8 hours (Table 3 and Table 4) after receiving the medicament.
Table 3 shows the results for group A and Table 4 shows the results for group B. The Tables show the number of patients whose symptoms were relieved for each symptom and sign after the dosages stated.
Table 3
Serial code No. Record of improvement in clinical features and investigations with treatment 1. Symptom and Sign DOSE improved Day 1 Day 2 Day 3 Day 4 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1.1. Fever 47 44 18 2 1.2. Chills 32 15 1.3. Cough 38 35 27 14 7 l.4 Nasal congestion 28 16 4 2 1.5. Sore throat 45 14 6 1 1.6. Tiredness 36 34 17 15 13 4 1.7. Nausea/Vomiting 19 5 2 1 1.8. Fatigue 41 3 14 3 1 1.9. Muscle/body pain 39 29 151 7 3 1.10. Diarrhea 14 3 1.11. Headache 31 16 3 1.12. Appetite 44 41 26 15 6 1.13. Taste 22 19 15 11 1.14. Smell 25 19 14 10 1.15. Concentration 31 22 13 3 1.16. Dyspnoea 33 28 13 4 1 1.17. Breath shortness 45 33 24 11 1 1.18. Chest pressure 23 12 4 1.19 Normal breathing 8 17 37 46 47 1.20. Sleep better 19 33 45 48 1.21 Sp02 90 93 96 2. Record of investigations Days Since Starting Treatment 4 7 14 21 CBC* 88 14 2.2. CRP** +Ve 98 Normal 2.3. RFT- Normal 2.4. PCR**** +Ve 100 -ye 100 2.5. Chest X-Ray +Ve 100 -ye 100 2.6. CT Scan +Ve 100 *CBC = complete blood count test **CRP = C-reactive protein test *""RFT = renal function test **""PCR = SARS-CoV-2 PCR test
Table 4
Serial code No. Record of improvement in clinical features and investigations with treatment 1. Symptom and Sign DOSE improved Day 1 Day 2 Day 3 Day 4 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1.1. Fever 85 28 17 5 1.2. Chills67 64 33 17 2 1.3. Cough 77 51 42 37 17 9 5 4 1 1.4. Nasal congestion 17 7 1.5. Sore throat 98 20 7 2 1.6. Tiredness 93 72 15 2 1.7. Nauseallomiting 17 4 2 1.8 Fatigue 94 54 13 5 1 9_ Muscle/body pain 83 71 36 12 3 1.10. Diarrhea 14 3 1 1.11. Headache 76 43 7 3 1.12. Appetite 84 53 22 7 3 2 1.13. Taste 53 44 43 28 15 1.14. Smell 61 55 41 38 32 28 1.15. Concentration 32 28 16 7 1.16. Dyspnoea 37 27 13 7 2 1.17. Breath shortness 54 43 26 15 7 2 1.18. Chest pressure 41 28 17 5 1 1.19 Normal breathing 28 37 45 94 98 1.20. Sleep better 29 38 45 51 67 97 121. Sp02 94 95 96 97 2. Record of investigations Days Since Starting Treatment 4 7 14 2.1. CBC 86 14 2.2. CRP +Ve 96 Normal 100 2.3. RFT Normal 2.4. PCR +Ve 100 -ye 100 2.5. Chest-Ray +Ve 100 -ye 100 2.6. CT Scan +Ve 100 From both results shown in Table 3 and Table 4, the respiratory complications were improved after 8 hours of receiving the medicament. Full relief of the COVID-19 symptoms from the patients was achieved after 2 or 3 days of receiving the medicament. No side effects were observed, nor complaints received from the patients. Furthermore, the patients' immune status was significantly improved after 36 hours of taking either the lozenge or the sachet medicament formulations. 95% of the patients' experienced that fevers were significantly and noticeably relieved after 4 hours (i.e. after the first medicament dosage). Overall results showed that both forms of the medicament formulations were found to be significant and have a "Curative Effect" against the COVID-19 infection caused by SARS-COV-2 virus. Furthermore, all patients showed a significant improvement in their immune systems.
Overall, the medicaments proved to be effective with potential efficacy to treat the symptoms associated with the COVID-19 caused by the SARS-CoV-2 virus.
Attention is directed to all papers and documents which are filed concurrently with or previous to this specification in connection with this application and which are open to public inspection with this specification, and the contents of all such papers and documents are incorporated herein by reference.
All of the features disclosed in this specification (including any accompanying claims, and drawings), and/or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and/or steps are mutually exclusive.
Each feature disclosed in this specification (including any accompanying claims, abstract and drawings) may be replaced by alternative features serving the same, equivalent or similar purpose, unless expressly stated otherwise. Thus, unless expressly stated otherwise, each feature disclosed is one example only of a generic series of equivalent or similar features.
The invention is not restricted to the details of the foregoing embodiment(s). The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.
Claims (14)
- Claims 1. A composition comprising: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina.
- 2. The composition according to claim 1, wherein the extract of Aucklandia lappa Decne and the extract of Punica granatum are provided in a weight ratio of from 4:1 to 1:1.
- 3. The composition according to any preceding claim, wherein the extract of Aucklandia lappa Decne is an extract of the root of Aucklandia lappa Decne, preferably an aqueous extract of the root of Aucklandia lappa Decne.
- 4. The composition according to any preceding claim, wherein the extract of Punica granatum is an extract of the peel of Punica granatum, preferably an aqueous extract of the peel of Punica granatum.
- 5. The composition according to any preceding claim, comprising an extract of Rhus coriaria L., an extract of Rhus glabra and an extract of Rhus typhina.
- 6. The composition according to claim 5, wherein the extracts of Rhus coriaria L, Rhus glabra and Rhus typhina are provided in a weight ratio of 1:1:1.
- 7 The composition according to any preceding claim consisting essentially of: (i) an extract of Aucklandia lappa Decne; (ii) an extract of Punica granatum; and (iii) an extract of Rhus coriaria L., an extract of Rhus glabra and an extract of Rhus typhina. 30
- 8. The composition according to any preceding claim, wherein the composition is for oral administration.
- 9. The composition according to any preceding claim for use as a medicament.
- 10. The composition according to any of claims 1 to 8 for use in the treatment of a respiratory tract infection, for example an upper and/or lower respiratory tract infection.
- 11. The composition according to any of claims 1 to 8 for use in the treatment of a coronavirus infection, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and/or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- 12. The composition for use according to claim 10 0111 which is orally administered once per day.
- 13. A method of preparing a lozenge comprising: admixing a therapeutically effective amount of a composition according to any of claims 1 to 7 with a lozenge base; and forming a lozenge.
- 14. A kit for providing a medicament (such as for oral administration), the kit comprising packaging containing: (i) an extract of Aucklandia lappa Decne; (H) an extract of Punica granatum; (iii) an extract of one or more of Rhus coriaria L., Rhus glabra and Rhus typhina; and (iv) instructions for administration of the medicament.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2209574.9A GB202209574D0 (en) | 2022-06-29 | 2022-06-29 | Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202309785D0 GB202309785D0 (en) | 2023-08-09 |
| GB2622130A true GB2622130A (en) | 2024-03-06 |
Family
ID=82705609
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2209574.9A Ceased GB202209574D0 (en) | 2022-06-29 | 2022-06-29 | Composition |
| GB2309785.0A Pending GB2622130A (en) | 2022-06-29 | 2023-06-28 | Composition |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2209574.9A Ceased GB202209574D0 (en) | 2022-06-29 | 2022-06-29 | Composition |
Country Status (1)
| Country | Link |
|---|---|
| GB (2) | GB202209574D0 (en) |
-
2022
- 2022-06-29 GB GBGB2209574.9A patent/GB202209574D0/en not_active Ceased
-
2023
- 2023-06-28 GB GB2309785.0A patent/GB2622130A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| Computers in Biology and Medicine, vol. 136, 2021, Belhassan, A. et al., Camphor, Artemisinin and Sumac: Phytochemicals as inhibitors against COVID-19: Computational approach, p. 1-17, article 104758. * |
| Journal of Nutrition and Metabolism, vol. 2022, 2022, Banihani, S.A., Possible beneficial effects of fresh pomegranate juice in SARS-CoV-2 infection conditions, p. 1-7. * |
| Sohag Medical Journal, vol. 24, no. 3, 2020, Saif-Al-Islam, M., Saussurea costus may help in the treatment of COVID-19, p. 6-17. * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB202209574D0 (en) | 2022-08-10 |
| GB202309785D0 (en) | 2023-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2500416C2 (en) | Compositions for preventing or relieving gastrointestinal diseases | |
| US10111451B2 (en) | Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor | |
| ES2381851T3 (en) | Procedure for obtaining an extract of blueberry pulp for use in the prevention and treatment of conditions such as caries, gingivitis and mild throat infections | |
| CN114502184A (en) | Pharmaceutical and food compositions for the prevention and treatment of coronavirus infection comprising Elaeagnus dulcis extract | |
| US20240082337A1 (en) | Composition for preventing or treating gastritis or peptic ulcer | |
| KR20160050108A (en) | Compositions for Improving Oral Hygiene comprising extracts derived from natural materials and Uses Thereof | |
| KR20160124007A (en) | Composition for preventing or treating inflammatory diseases or pain | |
| KR20150051369A (en) | Pharmaceutical composition for preventing or treating asthma or atopy comprising extract of Siraitia grosvenorii as an active ingradient | |
| KR20090050295A (en) | A composition for the prevention and treatment of edema or dermatitis containing glehnia littoralis fr. schmidt et miquel extract as an active ingredient | |
| KR20130097537A (en) | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory | |
| CN112641097A (en) | Composition with auxiliary protection effect on gastric mucosa injury and application thereof | |
| WO2005094858A1 (en) | Antidiabetic composition | |
| GB2622130A (en) | Composition | |
| KR102343245B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Chrysanthemum indicum L. oil extract as effective component | |
| KR101528557B1 (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
| KR101282356B1 (en) | Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease | |
| KR20130035371A (en) | Composition for improving allergic rhinitis and production method thereof | |
| KR101445177B1 (en) | A composition for treatment of disease of oral cavity containing extract of curcuma longa and opuntia humifusa | |
| KR20160020261A (en) | Composition for improving digestive functions comprising glabridin from Liquorice | |
| KR20150051367A (en) | Pharmaceutical composition for preventing or treating asthma or atopy comprising extract of Siraitia grosvenorii, Schisandra chinensis, and Platycodon grandiflorum as an active ingradient | |
| KR101760500B1 (en) | Oral composition for preventing or treating oral candidiasis comprising petal extract of Camellia sinensis as effective component | |
| KR20130131973A (en) | Anticariogenic composition comprising extract of bark of alnus japonica (thunberg) steudel | |
| CN113546137B (en) | A pharmaceutical composition for treating or preventing oral diseases | |
| KR100839099B1 (en) | Composition comprising an extract of galla rhois and moutan cortex radicis for preventing and treating the porcine epidemic diarrhea virus(pedv) | |
| KR20150111096A (en) | The pharmaceutical compositions for prevention or treatment of male infertility containing Rehmannia glutinosa Liboschitz var.purpurae Makino, Lycium chinense Miller, Aquillaria agallocha Roxburgh, Poria cocos Wolf, Panax ginseng C.A. Meyer and honey as a active ingredient |